| P50 | author | Sandro Mazzaferro | Q40837703 |
| | Mario Cozzolino | Q39187915 |
| P2093 | author name string | Vincent Brandenburg | |
| | Jordi Bover | |
| | Ziad A Massy | |
| | Tobias E Larsson | |
| | Marc G Vervloet | |
| | David Goldsmith | |
| | Pablo Ureña-Torres | |
| | CKD-MBD Working Group of ERA-EDTA | |
| P2860 | cites work | Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis | Q44871721 |
| | VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤ 150 pg/mL: results of the Italian FARO Survey | Q46291139 |
| | Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). | Q53214616 |
| | Bone-vascular axis in chronic kidney disease: a reality? | Q55051397 |
| | Use of phosphate-binding agents is associated with a lower risk of mortality | Q58946500 |
| | Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) | Q28236767 |
| | Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization | Q28283679 |
| | Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey | Q29614468 |
| | The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes | Q33989576 |
| | Phosphorus binders and survival on hemodialysis | Q34907022 |
| | Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population | Q35023526 |
| | Arterial calcification and bone physiology: role of the bone-vascular axis | Q36177303 |
| | The metabolic syndrome: a global public health problem and a new definition | Q36361180 |
| | Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status | Q37512120 |
| | Cystatin C versus creatinine in determining risk based on kidney function | Q37712784 |
| | Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement | Q37786856 |
| | Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat? | Q37835580 |
| | Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis | Q38122834 |
| | KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). | Q39886186 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1815-1820 | |
| P577 | publication date | 2014-02-09 | |
| P1433 | published in | Nephrology Dialysis Transplantation | Q15710302 |
| P1476 | title | Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome? | |
| P478 | volume | 29 | |